Discontinued — last reported Q3 '25
Royalty Pharma Equity Method Investments decreased by 8.4% to $265.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.0%, from $336.21M to $265.70M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows a downward trend with a -8.6% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $465.62M | $473.05M | $435.39M | $418.15M | $412.08M | $409.86M | $397.18M | $384.33M | $384.30M | $378.29M | $375.89M | $350.36M | $352.10M | $351.02M | $379.42M | $336.21M | $275.91M | $290.96M | $289.97M | $265.70M |
| QoQ Change | — | +1.6% | -8.0% | -4.0% | -1.5% | -0.5% | -3.1% | -3.2% | -0.0% | -1.6% | -0.6% | -6.8% | +0.5% | -0.3% | +8.1% | -11.4% | -17.9% | +5.5% | -0.3% | -8.4% |
| YoY Change | — | — | — | — | -11.5% | -13.4% | -8.8% | -8.1% | -6.7% | -7.7% | -5.4% | -8.8% | -8.4% | -7.2% | +0.9% | -4.0% | -21.6% | -17.1% | -23.6% | -21.0% |